Different Contributions of Clathrin- and Caveolae-mediated Endocytosis of Vascular Endothelial Cadherin to Lipopolysaccharide-induced Vascular Hyperpermeability
Overview
Authors
Affiliations
Vascular hyperpermeability induced by lipopolysaccharide (LPS) is a common pathogenic process in cases of severe trauma and sepsis. Vascular endothelial cadherin (VE-cad) is a key regulatory molecule involved in this process, although the detailed mechanism through which this molecule acts remains unclear. We assessed the role of clathrin-mediated and caveolae-mediated endocytosis of VE-cad in LPS-induced vascular hyperpermeability in the human vascular endothelial cell line CRL-2922 and determined that vascular permeability and VE-cad localization at the plasma membrane were negatively correlated after LPS treatment. Additionally, the loss of VE-cad at the plasma membrane was caused by both clathrin-mediated and caveolae-mediated endocytosis. Clathrin-mediated endocytosis was dominant early after LPS treatment, and caveolae-mediated endocytosis was dominant hours after LPS treatment. The caveolae-mediated endocytosis of VE-cad was activated through the LPS-Toll-like receptor 4 (TLR4)-Src signaling pathway. Structural changes in the actin cytoskeleton, specifically from polymerization to depolymerization, were important reasons for the switching of the VE-cad endocytosis pathway from clathrin-mediated to caveolae-mediated. Our findings suggest that clathrin-mediated and caveolae-mediated endocytosis of VE-cad contribute to LPS-induced vascular hyperpermeability, although they contribute via different mechanism. The predominant means of endocytosis depends on the time since LPS treatment.
Cervantes-Torres J, Hernandez-Aceves J, Gajon Martinez J, Moctezuma-Rocha D, Vazquez Ramirez R, Sifontes-Rodriguez S ACS Omega. 2024; 9(50):49625-49638.
PMID: 39713707 PMC: 11656211. DOI: 10.1021/acsomega.4c07736.
The Battle of LPS Clearance in Host Defense vs. Inflammatory Signaling.
Kumar P, Schroder E, Rajaram M, Harris E, Ganesan L Cells. 2024; 13(18.
PMID: 39329771 PMC: 11430141. DOI: 10.3390/cells13181590.
Erickson M, Shulyatnikova T, Banks W, Hayden M Int J Mol Sci. 2023; 24(2).
PMID: 36675154 PMC: 9862046. DOI: 10.3390/ijms24021640.
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.
Li Y, Zhang W, Zhao R, Zhang X Bioact Mater. 2022; 15:392-408.
PMID: 35386357 PMC: 8958389. DOI: 10.1016/j.bioactmat.2022.02.025.
Kondo-Kawai A, Sakai T, Terao J, Mukai R J Clin Biochem Nutr. 2021; 69(1):28-36.
PMID: 34376911 PMC: 8325769. DOI: 10.3164/jcbn.20-190.